Drugs / CTB-ACE2
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05433181 | Feb → Apr 2025 | COVID-19 | University of Pennsylvania | Withdrawn | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CTB-ACE2 | “CTB-ACE2, with efficient binding to both GM1 and ACE2 receptors, effectively blocks binding of the spike protein and viral entry into human cells.” NCT05433181 ↗ |
| Action | Inhibit | “effectively blocks binding of the spike protein and viral entry into human cells” NCT05433181 ↗ |
| Modality | Protein / enzyme biologic | “Angiotensin Converting Enzyme 2 expressed in lettuce chloroplasts” PMID 36314106 ↗ Dec 2022 |
| Route | Oral | “The IP is formulated as an oral plant powder” NCT05433181 ↗ |